Loading
A phase 3 trial of Mevrometostat, Enzalutamide in prostate cancer, run by Pfizer, now recruiting.
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. is a phase 3 interventional study registered as NCT07028853 by Pfizer, with 1000 participants planned, started 2025-09-28 and due to reach its primary completion in 2028-09-12. Interventions recorded: Mevrometostat, Placebo, Enzalutamide. Conditions listed: Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate. No results are recorded here; the registry entry is the source.
Shares Mevrometostat, Enzalutamide, Androgen deprivation & AR pathway inhibitors, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
Shares Mevrometostat, Enzalutamide, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Pfizer (incl. Seagen).
Shares Metastatic hormone-sensitive prostate cancer, Enzalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Metastatic hormone-sensitive prostate cancer, Enzalutamide, Androgen deprivation & AR pathway inhibitors, Pfizer (incl. Seagen).
Shares Enzalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Metastatic hormone-sensitive prostate cancer, Enzalutamide, Prostate cancer.
Shares Enzalutamide, Androgen deprivation & AR pathway inhibitors, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Prostate cancer.
Shares Metastatic hormone-sensitive prostate cancer, Androgen deprivation & AR pathway inhibitors, Prostate cancer.